Gut Microbiome & the Gut–Liver Axis: How Microbes Influence Liver Health

Your gut microbiome doesn’t just live in your intestines—it actively communicates with your liver through the gut–liver axis. This connection allows microbes and their byproducts to influence how your liver processes bile acids, metabolizes nutrients, and clears inflammatory signals. When the microbial ecosystem is balanced, it supports barrier function in the gut and promotes healthier immune regulation—both of which can help protect the liver.

But when the microbiome shifts out of balance (dysbiosis), the consequences can travel along the gut–liver axis. Increased intestinal permeability (“leaky gut”) can allow bacterial components to enter circulation and trigger liver inflammation. At the same time, altered fermentation and toxin metabolism can change which compounds reach the liver—potentially worsening fat buildup, oxidative stress, and signaling pathways linked to conditions such as fatty liver disease and heightened vulnerability to liver injury.

The good news: improving microbiome health may help strengthen the gut–liver relationship. Evidence-based strategies—like emphasizing fiber-rich, plant-based foods; supporting beneficial microbial metabolism of bile acids; and reducing dietary patterns that promote dysbiosis and inflammation—can help restore microbial balance. By targeting both gut ecosystems and the factors that drive liver inflammation, you can take meaningful steps toward better liver outcomes.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Gut-liver axis

The gut–liver axis describes bidirectional communication between the intestinal microbiome, gut barrier, and liver health. When the microbiome is balanced, it supports the gut lining, bile acid metabolism, and production of short-chain fatty acids (SCFAs) that help regulate inflammation. Dysbiosis can weaken the gut barrier, allowing microbial products like lipopolysaccharide (LPS) to reach the liver via the portal circulation, activating immune pathways (TLR signaling) and promoting inflammation, insulin resistance, and hepatic fat accumulation characteristic of MASLD/NAFLD. The axis also modulates bile acids through the conversion of primary to secondary bile acids, influencing receptors such as FXR and TGR5 and thereby affecting metabolism and gut–liver inflammation. Microbial metabolites and altered SCFA signaling can further impact liver injury risk and oxidative stress, tying dysbiosis to liver disease progression.

Common symptoms and prevalence: MASLD/NAFLD affects about 25% of adults globally, with gut–liver axis disruption linked to metabolic and inflammatory liver disease. People may experience bloating, changes in stool patterns, fatigue, abdominal discomfort, and right upper quadrant fullness. In advanced liver involvement, pruritus and jaundice can occur, though jaundice is relatively uncommon in the broader population. Microbiome testing can help determine whether dysbiosis and disrupted bile acid/SCFA signaling underlie these symptoms and guide dietary and lifestyle interventions.

Testing, mechanisms, and actions: The content highlights patterns of reduced beneficial taxa and elevated pro-inflammatory taxa associated with dysbiosis, decreased SCFA production, and impaired bile acid transformation. Microbiome testing (including tools like InnerBuddies) can provide actionable context to personalize diet—optimizing fiber sources and prebiotics, addressing factors that influence bile acid flow, and supporting liver-friendly microbial balance—while monitoring inflammatory tone and digestion-related symptoms over time. The evidence level is not numerically specified in the provided material.

Dysbiosis-induced gut barrier dysfunction enables microbial translocation (LPS and other components) to reach the liver, activating toll-like receptor signaling and promoting hepatic inflammation linked to MASLD/NAFLD.
Reduced short-chain fatty acid (SCFA) production, especially butyrate, weakens tight junctions and anti-inflammatory signaling, contributing to insulin resistance and hepatic fat accumulation.
Disrupted bile acid metabolism—less conversion of primary to secondary bile acids—blunts FXR/TGR5 signaling, altering metabolism and increasing gut–liver inflammation.
Dysbiosis shifts key microbial taxa: loss of beneficial, barrier-supporting genera (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes spp., Bifidobacterium spp., Akkermansia muciniphila, Blautia spp., Coprococcus spp.) and gain of potential pathogens (Enterobacteriaceae, Alistipes, Bilophila wadsworthia, Bacteroides fragilis group, Ruminococcus gnavus group, Streptococcus, Enterococcus, Clostridium clusters XIVa/IV), linking to barrier disruption and inflammation.
Altered immune regulation (including Th17/Treg balance) from gut–liver axis dysbiosis supports persistent low-grade inflammation and metabolic dysfunction.
Bile acid–microbiome interactions influence digestion, metabolism, and inflammatory tone, providing a mechanistic link between intestinal signals and liver health and MASLD/NAFLD risk.
Gut–liver axis microbiome testing can clarify dysbiosis patterns, guiding personalized dietary and microbiome-targeted strategies to support barrier integrity, SCFA production, and healthy bile acid signaling.
Dietary and microbiome-focused interventions (e.g., high-quality fiber, minimally processed foods, selective prebiotics/probiotics) may restore beneficial taxa and metabolic signaling, potentially slowing MASLD/NAFLD progression.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Gut-liver axis

It’s relevant for people dealing with gut–liver related health concerns—especially those with metabolic risk factors such as insulin resistance, abdominal weight gain, or signs of fatty liver (often MASLD/NAFLD). This includes individuals whose routine labs or imaging suggest liver inflammation or fat accumulation, and those noticing persistent GI symptoms alongside low energy or difficulty maintaining a healthy weight.

It’s also relevant for anyone experiencing symptoms that may reflect gut barrier dysfunction and gut dysbiosis, such as bloating, abdominal discomfort, and changes in stool pattern (diarrhea or constipation). When these symptoms occur together with right upper abdominal discomfort/fullness or nausea/reduced appetite, it may point to an imbalance in the gut microbiome and altered bile acid signaling—processes closely tied to liver immune activation and metabolic stress.

Consider it particularly relevant if symptoms suggest more advanced bile-related or inflammatory involvement, such as itching (pruritus) and jaundice (yellowing of the eyes/skin). People recovering from liver inflammation, hepatitis, or other conditions where oxidative stress and toxin handling may be affected may also benefit from a gut–liver axis perspective, since improving microbiome balance and supporting gut barrier integrity can influence how the liver responds over time.

Because the “gut–liver axis” is a mechanistic framework rather than a single disease, there is no single worldwide prevalence percentage for this indication itself. However, the conditions most commonly tied to gut–liver axis disruption—especially metabolic dysfunction–associated steatotic liver disease (MASLD/NAFLD)—are highly prevalent. Globally, MASLD affects about 25% of adults (roughly 1 in 4), with higher rates in people with obesity and insulin resistance, where gut dysbiosis and impaired gut barrier function are more common and more clinically relevant.

In people with MASLD/NAFLD, gastrointestinal symptoms often overlap with dysbiosis and altered motility, even though they are not specific enough to diagnose the condition on their own. Symptoms such as bloating, abdominal discomfort, and changes in stool pattern (diarrhea or constipation) are frequently reported in clinical practice, and population studies suggest that functional bowel symptoms are common in adults—often affecting a sizable minority (commonly in the range of ~10–20% depending on region and symptom definition). These bowel-pattern changes may co-occur with metabolic risk factors that also drive gut–liver axis strain (dietary patterns, low fiber intake, and metabolic dysregulation), which in turn is linked to liver inflammation progression.

Advanced liver involvement—where bile acids, inflammation, and immune activation are more pronounced—can produce symptoms that are less common but more recognizable, such as itching (pruritus) and jaundice. In the broader population, clinically apparent jaundice is relatively uncommon compared with nonspecific digestive symptoms; it typically occurs in a minority of people with liver disease and becomes more likely with significant cholestasis or hepatitis. Overall, while “gut–liver axis dysfunction” as a concept affects many individuals with dysbiosis and metabolic risk, the proportion who experience marked symptoms like jaundice is much smaller than the proportion with MASLD or with milder GI complaints.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Gut Microbiome & the Gut–Liver Axis: How Your Microbes Influence Liver Health

The gut–liver axis is the bidirectional communication between the intestinal microbiome, the gut barrier, and liver health. When gut microbes are balanced, they help maintain a strong intestinal lining and regulate bile acid metabolism and immune signaling. They also support the production of short-chain fatty acids (SCFAs), which can promote anti-inflammatory effects and help keep gut microbes and their byproducts from crossing into the bloodstream.

With gut dysbiosis—often marked by reduced microbial diversity and altered composition—the gut barrier can become more permeable. This can allow microbial products such as lipopolysaccharide (LPS) to reach the liver through portal circulation, a process often called microbial translocation. Once in the liver, LPS and other bacterial components can activate immune pathways (including toll-like receptor signaling), increasing inflammatory cytokines and contributing to metabolic stress, insulin resistance, and fat accumulation in the liver—processes central to metabolic dysfunction–associated steatotic liver disease (MASLD/NAFLD) and related conditions.

The microbiome also influences liver health by transforming primary bile acids into secondary bile acids that signal through receptors like FXR and TGR5, affecting both metabolism and gut–liver inflammation. When dysbiosis disrupts these bile acid pathways and SCFA production, protective signals may drop and inflammatory signaling can rise. This connection may help explain common symptoms such as bloating, changes in stool patterns, low energy, abdominal discomfort (including right upper quadrant fullness), and—when liver involvement is more advanced—itching and jaundice.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Gut Microbiome and Gut-liver axis

Microbial translocation due to impaired gut barrier: Dysbiosis reduces mucus/epithelial integrity and increases permeability, allowing microbial products (e.g., LPS) to reach the liver via portal circulation and trigger hepatic inflammation.
Toll-like receptor (TLR) and innate immune activation in the liver: LPS and other bacterial components activate TLR/NF-κB signaling, increasing inflammatory cytokines that drive metabolic dysfunction and promote steatosis.
Altered bile acid metabolism via microbiome: Gut bacteria convert primary to secondary bile acids, shaping signaling through FXR and TGR5; dysbiosis disrupts these pathways, reducing protective metabolic and anti-inflammatory effects.
Reduced short-chain fatty acid (SCFA) production: Lower SCFA output (e.g., acetate, propionate, butyrate) weakens anti-inflammatory signaling, impairs gut barrier support, and may worsen insulin resistance linked to MASLD.
Dysbiosis-driven changes in gut-derived metabolites that affect hepatic fat handling: Shifts in microbial metabolites can influence hepatic lipid uptake, de novo lipogenesis, and energy metabolism, accelerating fat accumulation.
Increased intestinal and hepatic immune crosstalk: Microbiome imbalance alters immune cell recruitment and activation (including Th17/Treg balance), sustaining chronic low-grade inflammation in the gut–liver axis.

The gut–liver axis is a two-way communication system linking intestinal microbes, the gut barrier, and liver immune/metabolic health. When the microbiome is balanced, it supports a resilient gut lining and helps regulate bile acid processing, while producing short-chain fatty acids (SCFAs) that promote anti-inflammatory signaling and help keep microbial byproducts contained. With dysbiosis—often involving reduced diversity and altered community structure—the gut barrier can weaken and become more permeable, enabling microbial components such as lipopolysaccharide (LPS) to cross into portal circulation and reach the liver (microbial translocation).

Once LPS and other bacterial products arrive in the liver, they can activate innate immune pathways, particularly toll-like receptor (TLR) signaling and downstream NF-κB activation. This promotes increased inflammatory cytokines and sustains chronic low-grade immune activation, which interferes with normal metabolic regulation. The resulting inflammatory pressure can contribute to insulin resistance and promote fat accumulation in the liver—key drivers in metabolic dysfunction–associated steatotic liver disease (MASLD/NAFLD). In parallel, dysbiosis can shift immune signaling across the gut and liver, including altered Th17/Treg balance, further reinforcing persistent gut–liver inflammation.

Beyond immune activation, the microbiome also shapes liver metabolism through bile acids and microbial metabolites. Gut bacteria transform primary bile acids into secondary bile acids that signal through receptors such as FXR and TGR5, pathways that influence glucose, lipid handling, bile acid homeostasis, and anti-inflammatory tone. Dysbiosis can disrupt these bile acid conversions and reduce protective signaling, while lower SCFA production (acetate, propionate, butyrate) weakens barrier-supporting and anti-inflammatory effects. Together, these changes can alter hepatic lipid uptake and energy metabolism, shifting the liver toward greater de novo lipogenesis and steatosis—helping explain gastrointestinal symptoms (e.g., bloating or stool changes) that may accompany or precede liver involvement.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Microbial patterns summary

In gut–liver axis dysfunction, a common pattern is gut dysbiosis characterized by reduced microbial diversity and a shift in community composition away from beneficial, barrier-supporting taxa. This imbalance is often accompanied by functional changes that lower the production of short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate, which normally help strengthen tight junctions and dampen inflammatory signaling. At the same time, dysbiosis can alter bile-acid–modifying activity, reducing the conversion of primary bile acids into secondary bile acids that engage protective metabolic and immune receptors.

As dysbiosis progresses, the gut barrier may become more permeable, creating a pattern consistent with “microbial translocation” where bacterial components like lipopolysaccharide (LPS) more readily reach the liver via portal circulation. This tends to correlate with microbial shifts that increase the relative presence or activity of LPS-producing Gram-negative organisms and/or reduce mucosal defenses that normally limit exposure to microbial byproducts. The result is a higher likelihood of toll-like receptor (TLR) activation in the liver, supporting chronic low-grade inflammatory signaling that can worsen insulin resistance and promote steatotic changes.

Another recurring microbial pattern in the gut–liver axis involves disruptions in bile acid and metabolite signaling that tie the intestine to hepatic metabolism. When microbial bile-acid transformation becomes inefficient, signaling through pathways such as FXR and TGR5 may weaken, and the anti-inflammatory “feedback loops” that help maintain metabolic balance can be impaired. Combined with reduced SCFA output and altered immune regulation (including shifts in gut-associated T cell balance), these changes often create an environment that favors hepatic fat accumulation and persistent inflammation, aligning with gastrointestinal symptoms like bloating or stool pattern changes that may accompany liver involvement.

Low beneficial taxa

Faecalibacterium prausnitzii
Roseburia spp.
Eubacterium rectale
Anaerostipes spp.
Bifidobacterium spp.
Akkermansia muciniphila
Blautia spp.
Coprococcus spp.

Elevated / overrepresented taxa

Enterobacteriaceae (e.g., Escherichia coli, Klebsiella species)
Alistipes spp.
Bilophila wadsworthia
Bacteroides fragilis group
Ruminococcus gnavus group
Streptococcus spp.
Enterococcus spp.
Clostridium cluster XIVa/IV (context-dependent; e.g., certain Clostridium species)

Functional pathways involved

SCFA biosynthesis (butyrate/propionate/acetate) and butyrate-mediated epithelial tight-junction support
Bile acid transformation (primary→secondary bile acids; bile-acid–modifying enzyme activity) and FXR/TGR5 signaling modulation
Microbial translocation and LPS-driven hepatic TLR4/NF-κB inflammatory signaling
Intestinal barrier function pathways (mucin/ mucus-layer integrity and antimicrobial defense) supporting reduced portal exposure to microbial products
Bacterial LPS and other endotoxin-related energy/metabolism pathways that increase Gram-negative burden
Microbial metabolism of tryptophan and indole derivatives influencing gut–immune regulation and hepatic inflammation (e.g., AhR-related signaling)
Uptake and metabolism of choline/carnitine to trimethylamine (TMA) and conversion to TMAO, linked to metabolic inflammation and insulin resistance

Diversity note

Gut–liver axis dysfunction is commonly associated with gut dysbiosis, where microbial diversity drops and the community shifts away from beneficial, barrier-supporting taxa. As diversity declines, the ecosystem becomes less resilient, and the balance of fermentative microbes that normally produce key metabolites can be disrupted. This often includes reduced generation of short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate, which support tight-junction integrity and help keep inflammatory signaling in check.

Along with lower diversity, dysbiosis frequently changes the relative abundance and activity of microbes involved in bile acid handling and immune stimulation. Inefficient bile-acid transformation can reduce the formation of secondary bile acids that normally activate protective signaling pathways (e.g., via FXR and TGR5). At the same time, shifts toward taxa that are more likely to contribute pro-inflammatory microbial components can further tip the system toward chronic low-grade inflammation.

As these changes progress, the gut barrier may become more permeable, increasing the likelihood of microbial byproducts reaching the liver through portal circulation. This pattern—often described as microbial translocation—tends to align with a less diverse, more imbalanced microbiome, where reduced SCFA-driven reinforcement and altered bile-acid signaling weaken the intestinal “filters” that limit exposure to compounds such as LPS. The result is a microbiome profile that supports greater hepatic toll-like receptor activation and sustained inflammatory tone, which can worsen metabolic stress and steatotic liver changes.

Take a Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

Issue with generic solutions

Generic “gut health” solutions often fail for the gut–liver axis because the problem is not just general dysbiosis—it’s the specific, bidirectional signaling between intestinal microbes, barrier integrity, and hepatic metabolism. Many broad approaches (for example, one-size-fits-all probiotics, generic fiber add-ons, or general detox/cleansing regimens) don’t reliably restore microbial diversity and function in the precise ways needed: lowering endotoxin/LPS pressure, rebuilding tight-junction strength, and improving gut-derived immunoregulatory signals that limit chronic low-grade inflammation reaching the liver.
They also miss the gut–bile acid component. In gut–liver dysfunction, microbial communities must correctly transform primary bile acids into secondary bile acids that signal through receptors such as FXR and TGR5, which help coordinate glucose/lipid metabolism and maintain immune tone. Generic gut interventions may increase stool frequency or change fermentation without restoring bile-acid–modifying pathways, leaving protective signaling weak while hepatic inflammatory and metabolic stress continues. Similarly, simply increasing fiber or using single nutrients may not correct the underlying functional deficits that reduce short-chain fatty acid (SCFA) production (e.g., butyrate/propionate/acetate), which are crucial for barrier function and anti-inflammatory signaling.
Finally, many approaches don’t account for “microbial translocation” dynamics—whether the gut barrier is truly leaky and how readily microbial products reach the liver via portal circulation. If someone’s issue is driven by mucus barrier impairment, altered immune signaling, or LPS-enriched microbial activity, generic strategies can provide incomplete relief or even worsen symptoms through poorly matched supplementation (e.g., provoking bloating in someone with fermentation sensitivity). Without targeting both barrier/metabolic signaling and bile-acid/immune pathways, generic solutions tend to produce inconsistent benefits and may not address the upstream drivers of MASLD/NAFLD-related inflammation.
Common mistakes
- Treating gut-liver axis dysfunction as generic dysbiosis (one-size-fits-all probiotics/synbiotics) without targeting the specific functional shifts tied to barrier integrity, LPS burden, and hepatic immune signaling
- Adding fiber or supplements without verifying SCFA-supportive functionality (e.g., not correcting reduced butyrate/propionate/acetate production), leading to weak tight-junction and anti-inflammatory effects
- Ignoring bile-acid transformation—failing to support microbial conversion of primary to secondary bile acids that drive protective FXR/TGR5 signaling, so metabolic/immune “feedback loops” remain impaired
- Failing to account for microbial translocation/leaky gut dynamics; using broad approaches that may increase fermentation or gut permeability in sensitive individuals, thereby sustaining or worsening LPS exposure to the liver
- Overlooking LPS/TLR activation drivers by not considering shifts toward LPS-producing Gram-negative activity and/or diminished mucosal defenses, resulting in incomplete reduction of chronic low-grade inflammation
- Using generic ‘detox/cleansing’ regimens instead of restoring microbial ecosystem function and metabolic signaling, which can temporarily change symptoms but not the underlying gut-liver communication
- Chasing symptom change (stool frequency, bloating, motility) rather than measuring or correcting upstream microbial functions (SCFAs, bile-acid metabolites, barrier/immune regulation), yielding inconsistent outcomes for MASLD/NAFLD-related pathways
- Not tailoring interventions to individual tolerance and fermentation capacity—adding prebiotic fibers or fermentable substrates that may worsen bloating in people whose barrier or bile-acid signaling is already dysregulated

What to do

General support strategies

Supporting the gut–liver axis starts with improving the health and resilience of the gut microbiome and the intestinal barrier. Diets that promote microbial diversity—such as those rich in fiber, diverse plant polyphenols, and adequate protein—help raise beneficial metabolite production, including short-chain fatty acids (SCFAs). These SCFAs support tight junction integrity, encourage an anti-inflammatory immune tone, and help limit microbial byproducts from crossing a more permeable gut lining. In parallel, reducing exposures that commonly worsen dysbiosis (for example, highly processed, low-fiber patterns, excess alcohol, and prolonged stress) can help lower the risk of microbial translocation, including gut-derived components like LPS reaching the liver via portal circulation.
Another core strategy is supporting bile acid signaling and efficient bile acid transformation. Gut microbes convert primary bile acids into secondary bile acids that activate receptors such as FXR and TGR5, which influence glucose and lipid metabolism as well as inflammatory pathways. When dysbiosis disrupts these processes, protective signaling may weaken and bile-acid–related gut and liver inflammation may increase. Approaches that encourage healthy microbial function—again often through fiber-first, microbiome-supportive nutrition and targeted nutrients with prebiotic effects—may help restore a more favorable bile acid profile and improve gut–liver communication.
Finally, overall metabolic and immune balance matters because gut–liver signaling is tightly linked to insulin sensitivity and hepatic inflammation. Supporting gut barrier function and SCFA production helps dampen toll-like receptor–mediated inflammatory cascades, which can contribute to metabolic stress and fat accumulation in the liver seen in MASLD/NAFLD. Practical lifestyle foundations—regular movement, sleep optimization, and moderation of alcohol—can complement nutrition by lowering systemic inflammation and helping maintain healthier gut–immune interactions. Together, these general strategies aim to reduce permeability-driven inflammation, improve bile acid signaling, and promote a more stable microbiome–liver relationship.
Lifestyle recommendations
- Follow a fiber-rich, plant-forward diet (legumes, vegetables, whole grains, nuts/seeds) to support microbial diversity and increase short-chain fatty acid (SCFA) production.
- Reduce intake of ultra-processed foods, added sugars, and refined carbohydrates to help limit dysbiosis, gut permeability, and liver fat accumulation.
- Aim for adequate hydration and regular meal timing; avoid frequent late-night eating to support bile flow and improve gut motility.
- Include fermented and probiotic foods when tolerated (e.g., yogurt/kefir, kimchi, sauerkraut) to help restore beneficial gut microbes.
- Limit alcohol (or avoid it if you have liver involvement) and avoid smoking to reduce gut-liver inflammatory signaling and further liver stress.
- Engage in regular physical activity (including both aerobic exercise and resistance training) to improve insulin sensitivity and reduce hepatic fat.
- Manage constipation and irregular stools (via fiber, fluids, and gentle activity); consider discussing targeted therapy with a clinician if persistent—this may reduce harmful microbial overgrowth.
Nutrition recommendations
- Prioritize a high-fiber, plant-forward diet (aim for a wide range of fruits, vegetables, legumes, whole grains) to support microbial diversity, strengthen the gut barrier, and increase beneficial SCFA production.
- Include prebiotic fibers regularly (e.g., inulin/chicory root, garlic, onions, leeks, asparagus, oats, bananas once ripe-to-slightly green) to promote growth of SCFA-producing bacteria.
- Consume fermented foods (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi, tempeh) to support a healthier gut microbial balance and reduce gut-derived inflammatory signaling.
- Optimize bile-acid support with healthy fats—especially omega-3s from fatty fish (or algae-based DHA/EPA)—and use extra-virgin olive oil; limit ultra-processed foods and excessive saturated/trans fats that can worsen metabolic inflammation and steatosis.
- Reduce endotoxin/LPS-promoting patterns by minimizing processed meats, deep-fried foods, and frequent added sugars; choose lean proteins (fish, poultry, legumes) and whole-food carbohydrates.
- Stay hydrated and limit alcohol intake (ideally avoid) to reduce gut barrier stress and liver inflammatory burden.
- If tolerated, consider targeted gut-supportive carbs and polyphenols (e.g., berries, citrus, pomegranate, green tea, coffee, herbs/spices) to enhance beneficial microbial metabolites and anti-inflammatory signaling.
Supplement considerations

For gut–liver axis support, supplements are often considered with the goal of improving microbial balance, strengthening the intestinal barrier, and reducing the likelihood of microbial products (like LPS) reaching the liver through portal circulation. In practice, this may involve approaches that increase beneficial gut microbes (e.g., targeted probiotics or spore-based strains) and provide prebiotic substrates that encourage diversity and SCFA production. SCFAs—especially butyrate—help nourish colon lining cells, support tight junction integrity, and can shift immune signaling toward a more anti-inflammatory tone, which is relevant to metabolic stress pathways linked to MASLD.
Because bile acids are a major communication channel between the gut and the liver, supplement strategies may also focus on optimizing bile acid metabolism and signaling. Nutrients or formulas that support healthy bile flow and microbial bile acid transformation can influence receptors such as FXR and TGR5, which help regulate glucose and lipid metabolism while modulating inflammatory responses in both the intestine and liver. Some people also consider agents aimed at binding excess bile acids in the gut to reduce reactivity, particularly when symptoms overlap with bile-acid–driven diarrhea, itching, or dysregulated stool patterns.
Finally, many gut–liver axis supplements are evaluated for their ability to calm downstream inflammatory signaling without overreacting to dysbiosis. Products with antioxidant and anti-inflammatory properties (for example, polyphenols or specific nutraceuticals studied for gut and hepatic protection) may complement microbiome-focused interventions by reducing oxidative stress and cytokine activity. As a precaution, individuals with advanced liver disease, those taking bile- or liver-affecting medications, or those with suspected bacterial overgrowth should tailor choices with clinical guidance, since altering gut ecology or bile handling can change symptoms and lab markers in either helpful or adverse directions.
Retesting / monitoring note

For the gut–liver axis, retesting is typically most useful after an interval that allows the gut microbiome, gut barrier function, and bile acid signaling to shift in response to an intervention (e.g., diet changes, probiotics/prebiotics, fiber targets, antimicrobial stewardship, or gut-directed therapies). In many cases, a retest window of about 8–12 weeks is reasonable to capture meaningful changes in microbial markers, intestinal permeability signals, and liver–inflammation readouts, since microbial composition and metabolite output (including short-chain fatty acids) often require several weeks to stabilize. If the results reflect a more advanced or unstable condition, clinicians may shorten the interval, while more stable cases may justify a longer follow-up after 12–16 weeks.
The most informative retesting strategy is to pair repeat measures of gut barrier and microbial translocation risk with liver-relevant markers tied to inflammation and bile acid metabolism. Depending on the specific panel used, this may include markers that reflect microbial byproduct load (such as LPS-related indicators or inflammatory pathway activity), stool- or microbiome-derived functional outputs (e.g., SCFA-associated profiles), and liver markers relevant to MASLD/NAFLD physiology (such as liver enzymes and metabolic inflammation markers). Retesting should ideally be timed when you can control confounders—recent antibiotics, acute infections, major dietary swings, changes in alcohol intake, or new medications (especially those affecting bile flow or immunity)—so that changes can be more confidently attributed to the gut–liver axis rather than short-term noise.
Finally, retesting should be approached as part of an iterative plan: results are used to refine targets and reassess whether the gut ecosystem and bile acid signaling are moving toward a more balanced state. If improvements are seen, a subsequent retest can be planned to confirm persistence (often another 3–6 months depending on baseline risk and severity). If results do not improve or worsen, retesting may be paired with a reassessment of adherence and a review of drivers of dysbiosis—such as low dietary fiber, constipation patterns, ongoing stress, poor sleep, or persistent reflux/IBS-like symptoms—along with clinician-guided adjustments to the treatment plan.

The importance of gut microbiome testing

Why testing matters

Gut microbiome testing matters for the gut–liver axis because it helps clarify whether dysbiosis is present—something that can directly influence gut barrier integrity, bile acid metabolism, and immune signaling that ultimately affects liver health. When microbial diversity and beneficial functions (such as SCFA production) are reduced, the intestinal lining can become more permeable, making microbial byproducts like LPS more likely to reach the liver via the portal circulation (microbial translocation). Testing can therefore provide insight into whether the microbiome is supporting anti-inflammatory conditions or, instead, potentially contributing to metabolic stress patterns linked with MASLD/NAFLD.
By identifying shifts in the microbiota that regulate bile acid transformation and receptor signaling (including pathways involving FXR and TGR5), microbiome results can also help explain why some people experience gut symptoms alongside signs that suggest liver involvement. Altered bile acid profiles can change digestion and motility while reducing protective signaling that normally helps modulate inflammation. Understanding these patterns may guide more targeted strategies—such as diet, fiber sources, and microbiome-supporting interventions—aimed at restoring more favorable bile acid and SCFA balance.
Finally, microbiome testing matters because it adds context to symptoms that often overlap across the gut–liver axis, such as bloating, stool changes, fatigue, abdominal discomfort, or right upper quadrant fullness. Rather than treating these symptoms in isolation, testing can help determine whether there are microbial signals consistent with increased inflammatory tone, impaired barrier support, or disrupted bile acid pathways—information that can improve personalization, monitor response over time, and support earlier, more precise efforts to protect liver health.
How InnerBuddies helps

InnerBuddies can help clarify whether your gut microbiome shows patterns of dysbiosis that may affect the gut–liver axis. Because gut microbes support intestinal barrier integrity and influence bile acid metabolism and immune signaling, the test can provide insight into whether beneficial, anti-inflammatory-oriented microbial activity is diminished and whether microbial imbalance could increase “leakiness”-related risk of microbial byproducts reaching the liver via portal circulation (often discussed as microbial translocation). This context can be especially valuable when you have symptoms commonly linked to this pathway—such as bloating, altered stool patterns, abdominal discomfort, fatigue, or right upper quadrant fullness—because it moves the conversation beyond symptoms alone.
In addition, InnerBuddies can help you understand whether microbial functions related to bile acid transformation and short-chain fatty acid (SCFA) production appear to be disrupted. SCFAs help support a healthier gut environment and can promote anti-inflammatory effects, while bile acids are key signaling molecules that regulate metabolism and inflammation through receptors like FXR and TGR5. When microbiome results suggest reduced SCFA-supporting activity or altered bile-acid–related processing, it may explain why some people experience overlapping gut and liver-metabolic stress patterns, which are relevant to MASLD/NAFLD risk and progression.
By turning microbiome signals into actionable context, InnerBuddies can support more targeted personalization of diet and microbiome-friendly interventions—such as adjusting fiber sources and prebiotic substrates, addressing diet patterns that influence bile acid flow, and targeting factors that shift microbial composition. This can be used both to guide early supportive strategies for gut–liver health and to monitor whether changes in your microbiome align with improvements in inflammatory tone and digestion-related symptoms over time.

Medical Evidence

Scientific evidence level

2 [weak—emerging but inconsistent]
Clinical relevance note

From a clinical standpoint, the gut–liver axis is biologically credible, and microbiome-based findings are frequently reported in liver diseases. However, current human evidence is not sufficiently consistent or rigorously causal for routine decision-making. Many associations likely reflect disease-related physiological changes (e.g., bile acid alterations, nutrition, medications, cirrhosis severity) rather than microbiome-driven causation.
At present, microbiome modulation has more convincing relevance for specific complications (notably hepatic encephalopathy) and for mechanistic/biochemical endpoints, but the evidence for improving major liver outcomes (progression to decompensation, fibrosis endpoints, transplant-free survival, and mortality) is not yet strong or consistently replicated. Measurement of the microbiome for clinical utility is therefore not validated broadly; significant gaps remain in assay standardization, external validation, reproducibility, and demonstrating that changes in microbiome features translate into sustained, clinically meaningful benefits.

Title	Journal	Year	Link
Metchnikoff revisited: gut microbiota and immunity in the liver	Nature Reviews Immunology	2015	View →
Translocation of intestinal bacteria and gut microbiota in portal hypertension and cirrhosis	Hepatology	2014	View →
Microbiome-based biomarkers for the identification of cirrhosis and hepatocellular carcinoma	Nature Communications	2014	View →
Gut microbiota and liver disease: from pathogenesis to therapy	Nature Reviews Gastroenterology & Hepatology	2014	View →
Gut microbiota contributes to the pathogenesis of non-alcoholic steatohepatitis	Gastroenterology	2006	View →

Frequently Asked Questions

¿Qué es el eje intestino‑hígado?

Es la comunicación bidireccional entre el microbioma intestinal, la barrera intestinal y el hígado que regula el metabolismo, la inmunidad y la señalización de ácidos biliares.

¿Cómo afecta la disbiosis intestinal al hígado?

Un desequilibrio de los microbios puede debilitar la barrera intestinal y enviar señales inflamatorias al hígado, favoreciendo la inflamación y la acumulación de grasa.

¿Qué es la translocación microbiana?

El paso de componentes bacterianos como LPS desde el intestino a la circulación portal y al hígado, a menudo cuando la barrera está permeable.

¿Qué papel juegan los ácidos biliares?

Los microbios transforman ácidos biliares primarios en secundarios, que activan receptores como FXR y TGR5 e influyen en el metabolismo y la inflamación.

¿Qué síntomas pueden indicar participación del eje intestino‑hígado?

Hinchazón, cambios en las heces, fatiga, sensación de plenitud en la región superior derecha, náuseas, picor y, en enfermedad avanzada, ictericia.

¿MASLD/NAFLD está relacionado con el microbioma?

Sí. la disbiose y una barrera intestinal comprometida se discuten con frecuencia en MASLD/NAFLD.

¿Cómo puede ayudarme la prueba del microbioma?

Puede revelar patrones de disbiosis, producción de SCFA y procesamiento de ácidos biliares para guiar ajustes dietéticos o de estilo de vida.

Señales de compromiso hepático avanzado como ictericia?

Ictericia, picor intenso, orina oscura y heces claras; consulta médica necesaria.

¿Qué cambios de estilo de vida apoyan la salud intestino‑hígado?

Dieta rica en fibra, mínimamente procesada; limitar alcohol y azúcares; mantener un peso saludable; actividad física regular.

¿Pueden ayudar los probióticos o prebióticos?

Pueden ayudar a algunas personas; los efectos varían; consulta con un profesional sobre cepas y dosis adecuadas.

¿Cómo se relaciona la producción de SCFA con la salud de la barrera intestinal?

Los SCFA, especialmente el butirato, ayudan a mantener el revestimiento intestinal y reducen la inflamación.

¿Qué son FXR y TGR5 y por qué importan?

Son receptores activados por ácidos biliares que regulan el metabolismo y la inflamación; los microbios influyen en su señalización.

¿Cómo se vincula la inflamación con la resistencia a la insulina?

Los productos microbianos pueden activar rutas inmunitarias en el hígado y otros tejidos, promoviendo la resistencia a la insulina y la acumulación de grasa.

¿Cómo puede ayudar InnerBuddies?

Analiza patrones del microbioma relacionados con la barrera, el procesamiento de ácidos biliares y la producción de SCFA para estrategias personalizadas.

¿Hay limitaciones en las pruebas del microbioma?

Sí; son instantáneas y pueden variar; una prueba por sí sola no diagnóstico una enfermedad.

¿Las personas con enfermedad hepática deben preocuparse por la salud intestinal?

Mantener la salud intestinal es parte de la salud hepática; consulte a un profesional para un plan individual.

¿Cómo diferenciar los síntomas del eje intestino‑hígado de otros trastornos GI?

Muchos síntomas se superponen; hable de la duración y el patrón con un profesional para ayudar a diferenciar.

¿Con qué frecuencia se deben repetir las pruebas del microbioma?

Depende de los objetivos; a veces entre 3 y 12 meses.

¿Qué alimentos aumentan la producción de SCFA o apoyan la barrera intestinal?

Fibra de origen vegetal: verduras, frutas, granos enteros, legumbres; variedad de alimentos vegetales.

¿Puede el eje intestino‑hígado influir en otras condiciones hepáticas?

Está bien estudiado en MASLD/NAFLD; podría haber efectos en otras inflamaciones hepáticas.

Hear from our satisfied customers!

"I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"
- Manon, age 29 -
"Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."
- Petra, age 68 -
"I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."
- Dirk, age 73 -

Idioma

Gut Microbiome & the Gut–Liver Axis: How Microbes Influence Liver Health

Gut-liver axis

Other liver-related topics

Gut-liver axis

Gut Microbiome & the Gut–Liver Axis: How Your Microbes Influence Liver Health

Gut Microbiome and Gut-liver axis

Why generic solutions fail

Issue with generic solutions

Common mistakes

What to do

General support strategies

Lifestyle recommendations

Nutrition recommendations

Supplement considerations

Retesting / monitoring note

The importance of gut microbiome testing

Why testing matters

How InnerBuddies helps

Medical Evidence

Scientific evidence level

Clinical relevance note

Frequently Asked Questions

Hear from our satisfied customers!